The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

The Lancet Psychiatry

Volumn 5, Issue 12, 2018, Pages 987-1012

  Degenhardt, Louisa ^a   Charlson, Fiona ^a   Ferrari, Alize ^a   Santomauro, Damian ^a   Erskine, Holly ^a   Mantilla Herrara, Ana ^a   Whiteford, Harvey ^a   Leung, Janni ^a   Naghavi, Mohsen ^a   Griswold, Max ^a   Rehm, Jürgen ^a   Hall, Wayne ^a   Sartorius, Benn ^a   Scott, James ^a   Vollset, Stein Emil ^a   Knudsen, Ann Kristin ^a   Haro, Josep Maria ^a   Patton, George ^a   Kopec, Jacek ^a   Carvalho Malta, Deborah ^a   Topor Madry, Roman ^a,b   McGrath, John ^a   Haagsma, Juanita ^a   Allebeck, Peter ^a   Phillips, Michael ^a   Salomon, Joshua ^a   Hay, Simon ^a   Foreman, Kyle ^a   Lim, Stephen ^a   Mokdad, Ali ^a   Smith, Mari ^a   Gakidou, Emmanuela ^a   Murray, Christopher ^a   Vos, Theo ^a   more..

^a Jagiellonian University Medical College ^*

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEPATITIS B; ACUTE HEPATITIS C; ALCOHOL CONSUMPTION; ALCOHOLISM; AMPHETAMINE DEPENDENCE; ARTICLE; AUTOMUTILATION; CANNABIS ADDICTION; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISABILITY; DISABILITY-ADJUSTED LIFE YEAR; DRUG DEPENDENCE; EPILEPSY; GLOBAL DISEASE BURDEN; HUMAN; INCIDENCE; INJURY; LIVER CANCER; LIVER CIRRHOSIS; LOWER RESPIRATORY TRACT INFECTION; MORTALITY; NEOPLASM; OPIATE ADDICTION; PANCREATITIS; PREVALENCE; PRIORITY JOURNAL; PUBLIC POLICY; REMISSION; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TUBERCULOSIS; ADULT; FEMALE; GLOBAL HEALTH; MALE; MIDDLE AGED; QUALITY ADJUSTED LIFE YEAR;

ADULT; ALCOHOLISM; FEMALE; GLOBAL BURDEN OF DISEASE; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE-RELATED DISORDERS;

EID: 85057201843     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(18)30337-7     Document Type: Article

References (64)

1. Rehm, J, Gmel, GE Sr, Gmel, G, et al. The relation between different dimensions of alcohol consumption and burden of disease: an update. Addiction 112 (2017), 968–1001.
2. Degenhardt, L, Hall, W, Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379 (2012), 55–70.
3. WHO. The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research. 1993, World Health Organization, Geneva.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th edn., 2000, American Psychiatric Association, Washington DC.
5. Larney, S, Peacock, A, Mathers, BM, Hickman, M, Degenhardt, L, A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend 171 (2017), 39–49.
6. Rehm, J, Baliunas, D, Borges, GL, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 105 (2010), 817–843.
7. Nutt, D, King, L, Phillips, L, Drug harms in the UK: a multicriteria decision analysis. Lancet 376 (2010), 1558–1565.
8. World Bank. World Development Report 1993: investing in health. 1993, Oxford University Press, New York.
9. Murray, CJ, Lopez, AD, On the comparable quantification of health risks: lessons from the Global Burden of Disease Study. Epidemiology 10 (1999), 594–605.
10. Stevens, GA, Alkema, L, Black, RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet 388 (2016), e19–e23.
11. Vos, T, Abajobir, AA, Abate, KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1211–1259.
12. Naghavi, M, Abajobir, AA, Abbafati, C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1151–1210.
13. Hay, SI, Abajobir, AA, Abate, KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1260–1344.
14. Gakidou, E, Afshin, A, Abajobir, AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1345–1422.
15. Popova, S, Lange, S, Shield, K, et al. Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis. Lancet 387 (2016), 978–987.
16. Wang, H, Abajobir, AA, Abate, KH, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (2017), 1084–1150.
17. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269.
18. Flaxman, AD, Vos, DT, Murray, CJ, An integrative metaregression framework for descriptive epidemiology. 2015, University of Washington Press, Seattle.
19. Degenhardt, L, Bucello, C, Calabria, B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 117 (2011), 85–101.
20. Salomon, JA, Haagsma, JA, Davis, A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3 (2015), e712–e723.
21. Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2129–2143.
22. Haagsma, JA, De Noordhout, CM, Polinder, S, et al. Assessing disability weights based on the responses of 30,660 people from four European countries. Popul Health Metr, 13, 2015, 10.
23. Hasin, DS, Grant, BF, The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol 50 (2015), 1609–1640.
24. Shand, F, Degenhardt, L, Nelson, E, Mattick, R, Predictors of social anxiety in an opioid dependent sample and a control sample. J Anxiety Disord 24 (2010), 49–54.
25. Shand, F, Slade, T, Degenhardt, L, Baillie, A, Nelson, E, Opioid dependence latent structure: two classes with differing severity?. Addiction 106 (2011), 590–598.
26. Fullman, N, Barber, RM, Abajobir, AA, et al. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet 390 (2017), 1423–1459.
27. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2018 published online Aug 23. http://dx.doi.org/10.1016/S0140-6736(18)31310-2.
28. Murray, CJ, Ezzati, M, Lopez, AD, Rodgers, A, Vander Hoorn, S, Comparative quantification of health risks: conceptual framework and methodological issues. Popul Health Metr, 1, 2003, 1.
29. Rehm, J, Kehoe, T, Gmel, G, Stinson, F, Grant, B, Gmel, G, Statistical modeling of volume of alcohol exposure for epidemiological studies of population health: the US example. Popul Health Metr, 8, 2010, 3.
30. Shield, KD, Rylett, M, Gmel, G, Gmel, G, Kehoe-Chan, TA, Rehm, J, Global alcohol exposure estimates by country, territory and region for 2005—a contribution to the Comparative Risk Assessment for the 2010 Global Burden of Disease Study. Addiction 108 (2013), 912–922.
31. Degenhardt, L, Charlson, F, Stanaway, J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 16 (2016), 1385–1398.
32. Agardh, EE, Danielsson, AK, Ramstedt, M, et al. Alcohol-attributed disease burden in four Nordic countries: a comparison using the Global Burden of Disease, Injuries and Risk Factors 2013 study. Addiction 111 (2016), 1806–1813.
33. Wang, PS, Angermeyer, M, Borges, G, et al. Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry, 6, 2007, 177.
34. Degenhardt, L, Glantz, M, Evans-Lacko, S, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry 16 (2017), 299–307.
35. Rehm, J, Shield, K, Gmel, G, Rehm, M, Frick, U, Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacology 23 (2013), 89–97.
36. Larney, S, Peacock, A, Leung, J, et al. Gobal, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 5 (2017), e1208–e1220.
37. Jernigan, DH, Babor, TF, The concentration of the global alcohol industry and its penetration in the African region. Addiction 110 (2015), 551–560.
38. Bakke, Ø Endal, D, Vested interests in addiction research and policy alcohol policies out of context: Drinks industry supplanting government role in alcohol policies in sub-Saharan Africa. Addiction 105 (2010), 22–28.
39. Hanefeld, J, Hawkins, B, Knai, C, Hofman, K, Petticrew, M, What the InBev merger means for health in Africa. BMJ Glob Health, 1, 2016, e000099.
40. The Lancet. A framework convention on alcohol control. Lancet, 370, 2007, 1102.
41. Anderson, P, Chisholm, D, Fuhr, DC, Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 373 (2009), 2234–2246.
42. Rehm, J, Lachenmeier, DW, Llopis, EJ, Imtiaz, S, Anderson, P, Evidence of reducing ethanol content in beverages to reduce harmful use of alcohol. Lancet Gastroenterol Hepatol 1 (2016), 78–83.
43. Purshouse, RC, Meier, PS, Brennan, A, Taylor, KB, Rafia, R, Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model. Lancet 375 (2010), 1355–1364.
44. Kohn, R, Saxena, S, Levav, I, Saraceno, B, The treatment gap in mental health care. Bull World Health Organ 82 (2004), 858–866.
45. Morley, KC, Logge, W, Pearson, S-A, Baillie, A, Haber, PS, National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug Alcohol Depend 166 (2016), 254–257.
46. Gates, PJ, Sabioni, P, Copeland, J, Le Foll, B, Gowing, L, Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev, 5, 2016 CD005336.
47. Minozzi, S, Saulle, R, De Crescenzo, F, Amato, L, Psychosocial interventions for psychostimulant misuse. Cochrane Database Syst Rev, 9, 2016 CD011866.
48. Degenhardt, L, Bucello, C, Mathers, B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 106 (2011), 32–51.
49. Mattick, RP, Breen, C, Kimber, J, Davoli, M, Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev, 3, 2009 CD002209.
50. Mattick, RP, Kimber, J, Breen, C, Davoli, M, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev, 2, 2008 CD002207.
51. McDonald, R, Campbell, ND, Strang, J, Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation. Drug Alcohol Depend 178 (2017), 176–187.
52. MacArthur, GJ, Minozzi, S, Martin, N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ, 345, 2012, e5945.
53. Gowing, L, Farrell, MF, Bornemann, R, Sullivan, LE, Ali, R, Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev, 8, 2011 CD004145.
54. Degenhardt, L, Mathers, B, Vickerman, P, Rhodes, T, Latkin, C, Hickman, M, Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376 (2010), 285–301.
55. Turner, KM, Hutchinson, S, Vickerman, P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106 (2011), 1978–1988.
56. Degenhardt, L, Mathers, BM, Wirtz, AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy 25 (2014), 53–60.
57. Martin, NK, Vickerman, P, Dore, GJ, Hickman, M, The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS 10 (2015), 374–380.
58. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edn., 2013, American Psychiatric Association, Washington, DC.
59. Lago, L, Bruno, R, Degenhardt, L, Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. Lancet Psychiatry 3 (2016), 673–684.
60. Goldstein, RB, Chou, SP, Smith, SM, et al. Nosologic comparisons of DSM-IV and DSM-5 alcohol and drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. J Stud Alcohol Drugs 76 (2015), 378–388.
61. Lundin, A, Hallgren, M, Forsman, M, Forsell, Y, Comparison of DSM-5 classifications of alcohol use disorders with those of DSM-IV, DSM-III-R, and ICD-10 in a general population sample in Sweden. J Stud Alcohol Drugs 76 (2015), 773–780.
62. Degenhardt L, Bharat C, Bruno R, et al. Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. Addiction (in press).
63. WHO. The health and social effects of nonmedical cannabis use. 2016, World Health Organization, Geneva.
64. Darke, S, Kaye, S, McKetin, R, Duflou, J, Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27 (2008), 253–262.